The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

doi:10.1186/s40425-016-0198-x

. 2016 Dec 20:4:92.

doi: 10.1186/s40425-016-0198-x. eCollection 2016.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Douglas G McNeel¹, Neil H Bander², Tomasz M Beer³, Charles G Drake⁴, Lawrence Fong⁵, Stacey Harrelson⁶, Philip W Kantoff⁷, Ravi A Madan⁸, William K Oh⁹, David J Peace¹⁰, Daniel P Petrylak¹¹, Hank Porterfield¹², Oliver Sartor¹³, Neal D Shore⁶, Susan F Slovin⁷, Mark N Stein¹⁴, Johannes Vieweg¹⁵, James L Gulley¹⁶

Affiliations

¹ University of Wisconsin Carbone Cancer Center, 7007 WIMR, 1111 Highland Avenue, Madison, WI 53705 USA.
² Weill Medical College of Cornell University, Laboratory of Urological Oncology E-300, 525 East 68th Street, New York, NY 10021 USA.
³ Oregon Health and Science University Knight Cancer Institute, 3181 SW Sam Jackson Park Road, Portland, OR 97239 USA.
⁴ Johns Hopkins University, 1650 Orleans Street Room 410, Baltimore, MD 21287 USA.
⁵ University of California, San Francisco, 513 Parnassus Ave, Room HSF 301, Box 1270, San Francisco, CA 94143 USA.
⁶ Carolina Urologic Research Center, 823 82nd Parkway, Suite B, Myrtle Beach, SC 29572 USA.
⁷ Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 USA.
⁸ National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892 USA.
⁹ Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1079, New York, NY 10029 USA.
¹⁰ University of Illinois, 840 S Wood Street, Suite 820, Chicago, IL 60612 USA.
¹¹ Yale Cancer Center, PO Box 208032, New Haven, CT 06520 USA.
¹² Alliance for Prostate Cancer Prevention, 17660 Tamiami Trail, Suite 106, Fort Myers, FL 33908 USA.
¹³ Tulane University School of Medicine, 1430 Tulane Ave, SL-42, New Orleans, LA 70112 USA.
¹⁴ Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903 USA.
¹⁵ Nova Southeastern University, 3200 South University Drive, Fort Lauderdale, FL 33328 USA.
¹⁶ Genitourinary Malignancies Branch, 10 Center Drive, 13N240, Bethesda, MD 20892 USA.

PMID: 28031820
PMCID: PMC5170901
DOI: 10.1186/s40425-016-0198-x

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Douglas G McNeel et al. J Immunother Cancer. 2016.

. 2016 Dec 20:4:92.

doi: 10.1186/s40425-016-0198-x. eCollection 2016.

Authors

Affiliations

¹ University of Wisconsin Carbone Cancer Center, 7007 WIMR, 1111 Highland Avenue, Madison, WI 53705 USA.
² Weill Medical College of Cornell University, Laboratory of Urological Oncology E-300, 525 East 68th Street, New York, NY 10021 USA.
³ Oregon Health and Science University Knight Cancer Institute, 3181 SW Sam Jackson Park Road, Portland, OR 97239 USA.
⁴ Johns Hopkins University, 1650 Orleans Street Room 410, Baltimore, MD 21287 USA.
⁵ University of California, San Francisco, 513 Parnassus Ave, Room HSF 301, Box 1270, San Francisco, CA 94143 USA.
⁶ Carolina Urologic Research Center, 823 82nd Parkway, Suite B, Myrtle Beach, SC 29572 USA.
⁷ Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 USA.
⁸ National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892 USA.
⁹ Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1079, New York, NY 10029 USA.
¹⁰ University of Illinois, 840 S Wood Street, Suite 820, Chicago, IL 60612 USA.
¹¹ Yale Cancer Center, PO Box 208032, New Haven, CT 06520 USA.
¹² Alliance for Prostate Cancer Prevention, 17660 Tamiami Trail, Suite 106, Fort Myers, FL 33908 USA.
¹³ Tulane University School of Medicine, 1430 Tulane Ave, SL-42, New Orleans, LA 70112 USA.
¹⁴ Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903 USA.
¹⁵ Nova Southeastern University, 3200 South University Drive, Fort Lauderdale, FL 33328 USA.
¹⁶ Genitourinary Malignancies Branch, 10 Center Drive, 13N240, Bethesda, MD 20892 USA.

PMID: 28031820
PMCID: PMC5170901
DOI: 10.1186/s40425-016-0198-x

Abstract

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly.

Keywords: Guidelines; Immunotherapy; Prostate Cancer; Treatment.

PubMed Disclaimer

Figures

**Fig. 1**
Treatment algorithm for prostate cancer. Abbreviations: radiation therapy (RT), radical prostatectomy (RP), active surveillance (AS). Asterisk (*) indicates with continuous testosterone suppression, with or without denosumab or zoledronic acid

See this image and copyright information in PMC

Cited by

Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.
Eckert F, Schaedle P, Zips D, Schmid-Horch B, Rammensee HG, Gani C, Gouttefangeas C. Eckert F, et al. Oncoimmunology. 2018 Aug 27;7(11):e1496881. doi: 10.1080/2162402X.2018.1496881. eCollection 2018. Oncoimmunology. 2018. PMID: 30393582 Free PMC article.
Landscape of Immunotherapy in Genitourinary Malignancies.
Ravindranathan D, Alhalabi O, Rafei H, Shah AY, Bilen MA. Ravindranathan D, et al. Adv Exp Med Biol. 2021;1342:143-192. doi: 10.1007/978-3-030-79308-1_5. Adv Exp Med Biol. 2021. PMID: 34972965 Free PMC article. Review.
Potentiating prostate cancer immunotherapy with oncolytic viruses.
Lee P, Gujar S. Lee P, et al. Nat Rev Urol. 2018 Apr;15(4):235-250. doi: 10.1038/nrurol.2018.10. Epub 2018 Feb 13. Nat Rev Urol. 2018. PMID: 29434366 Review.
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Hendry S, et al. Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Adv Anat Pathol. 2017. PMID: 28777143 Free PMC article. Review.
Management algorithms for metastatic prostate cancer.
Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So AI, Park-Wyllie L, Hew H, McLeod D, Gotto G. Malone S, et al. Can Urol Assoc J. 2020 Feb;14(2):50-60. doi: 10.5489/cuaj.5840. Can Urol Assoc J. 2020. PMID: 31039111 Free PMC article. Review.

See all "Cited by" articles

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi: 10.3322/caac.21332. - DOI - PubMed
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254. - DOI - PubMed
1. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548–52. doi: 10.1001/jama.1995.03520310046028. - DOI - PubMed
1. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. doi: 10.1056/NEJMoa1207506. - DOI - PubMed
1. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92. doi: 10.1016/S1470-2045(12)70379-0. - DOI - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- ClinicalTrials.gov
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi: 10.3322/caac.21332. - DOI - PubMed

[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi: 10.3322/caac.21332. - DOI - PubMed

[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254. - DOI - PubMed

[4] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 10.3322/caac.21254. - DOI - PubMed

[5] Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548–52. doi: 10.1001/jama.1995.03520310046028. - DOI - PubMed

[6] Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548–52. doi: 10.1001/jama.1995.03520310046028. - DOI - PubMed

[7] Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. doi: 10.1056/NEJMoa1207506. - DOI - PubMed

[8] Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. doi: 10.1056/NEJMoa1207506. - DOI - PubMed

[9] Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92. doi: 10.1016/S1470-2045(12)70379-0. - DOI - PubMed

[10] Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92. doi: 10.1016/S1470-2045(12)70379-0. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Affiliations

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Abstract

Figures

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials